NYSE · OGN
Healthcare · Drug Manufacturers - General
$13.74
Up+$0.02 (+0.11%)
Updated Oct 15, 2026, 6:40 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OGN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 14, 2026
OGN closed at $13.74 after 21 trading sessions, up 0.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 14, 2026 | $13.77 | $13.77 | $13.74 | $13.74 | 1.81M |
| Oct 13, 2026 | $13.77 | $13.79 | $13.76 | $13.77 | 2.89M |
| Oct 12, 2026 | $13.80 | $13.80 | $13.76 | $13.77 | 932.35K |
| Oct 9, 2026 | $13.76 | $13.83 | $13.75 | $13.81 | 3.26M |
| Oct 8, 2026 | $13.78 | $13.80 | $13.75 | $13.75 | 2.09M |
| Oct 7, 2026 | $13.72 | $13.79 | $13.72 | $13.79 | 2.21M |
| Oct 6, 2026 | $13.74 | $13.75 | $13.73 | $13.74 | 1.95M |
| Oct 5, 2026 | $13.72 | $13.75 | $13.70 | $13.70 | 2.88M |
| Oct 2, 2026 | $13.71 | $13.75 | $13.71 | $13.72 | 1.92M |
| Oct 1, 2026 | $13.71 | $13.74 | $13.71 | $13.71 | 2.1M |
| Sep 30, 2026 | $13.74 | $13.76 | $13.70 | $13.70 | 2.07M |
| Sep 29, 2026 | $13.73 | $13.75 | $13.72 | $13.74 | 1.63M |
| Sep 28, 2026 | $13.75 | $13.75 | $13.72 | $13.73 | 1.99M |
| Sep 25, 2026 | $13.74 | $13.74 | $13.70 | $13.73 | 1.39M |
| Sep 24, 2026 | $13.72 | $13.74 | $13.72 | $13.72 | 2.22M |
| Sep 23, 2026 | $13.71 | $13.74 | $13.70 | $13.73 | 983.34K |
| Sep 22, 2026 | $13.70 | $13.72 | $13.68 | $13.70 | 1.37M |
| Sep 21, 2026 | $13.70 | $13.76 | $13.67 | $13.68 | 3.12M |
| Sep 18, 2026 | $13.68 | $13.70 | $13.68 | $13.68 | 4.94M |
| Sep 17, 2026 | $13.67 | $13.69 | $13.66 | $13.69 | 1.26M |
| Sep 16, 2026 | $13.65 | $13.68 | $13.65 | $13.67 | 2.07M |
The latest Smart Investors Daily articles mentioning OGN.
Company
Market Activity
Research & News
OGN research
Company profile and research snapshot.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | Neutral | — |
| Apr 28, 2026 | Piper Sandler | Neutral | — |
| Feb 24, 2026 | Barclays | Underweight | — |
| Dec 9, 2025 | Barclays | Underweight | — |
| Nov 11, 2025 | JP Morgan | Underweight | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Yahoo · Oct 1, 2026
JERSEY CITY, N.J., October 01, 2026--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.
Yahoo · Sep 28, 2026
Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric patients 2 years of age and older.
Benzinga · Sep 28, 2026
Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OGN.
